Stoke Therapeutics
STOK
Market cap $630M

11.53 USD

-0.29

2.45%

At close Jun 13, 4:00 PM EDT

After hours

11.53

+0.00

0.00%

1 day

-2.45%

5 days

1.95%

1 month

29.12%

3 months

42.17%

6 months

-4.39%

Year to date

2.31%

1 year

-34.19%

5 years

-50.66%

10 years

-54.91%

About: Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Employees: 128

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

7.59% more ownership

Funds ownership: 109.61% [Q4 2024] → 117.21% (+7.59%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

7% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 27

2% less funds holding

Funds holding: 130 [Q4 2024] → 127 (-3) [Q1 2025]

34% less capital invested

Capital invested by funds: $640M [Q4 2024] → $422M (-$219M) [Q1 2025]

94% less call options, than puts

Call options by funds: $60K | Put options by funds: $973K

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

91%

upside

Avg. target

$27

134%

upside

High target

$35

204%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Andrew Fein	204%upside $35	Buy Maintained	14 May 2025
Needham Joseph Stringer	91%upside $22	Buy Reiterated	9 Apr 2025
Chardan Capital Rudy Li	108%upside $24	Buy Maintained	19 Mar 2025

See Analyst Rankings

Financial journalist opinion

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Jefferies Global Healthcare Conference on Wednesday, June.

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

Zacks Investment Research

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.57 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2025, and provided business updates. “The first quarter was defined by s.

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks Investment Research

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Stoke Therapeutics (STOK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stoke Therapeutics (STOK) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

Stoke Therapeutics (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Stoke Therapeutics (STOK) Soars 12.0%: Is Further Upside Left in the Stock?

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the 24th Annual Needham Virtual Healthcare Conference on Tues.

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Stock Slips as CEO Steps Down

Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.

Stoke Therapeutics Stock Slips as CEO Steps Down

Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™